PharVision Advisers’s Qualys QLYS Stock Holding History

PharVision Advisers’s Portfolio QLYS Stock Details QLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,811	Closed	-$228K	–	397
2025 Q1	$228K	Buy	+1,811	New	+$245K	0.32%	159

Other funds holding QLYS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PharVision Advisers's QLYS Position: Q2 2025 in Review

PharVision Advisers sold out of Qualys (QLYS) in Q2 2025, closing a stake of 1,811 shares — an estimated $228K sold.

PharVision Advisers first reported a position in QLYS in Q1 2025 and held it in 1 quarter. The position peaked at $228K in Q1 2025. 436 funds tracked by Wall St. Rank hold QLYS as of Q2 2025.

PharVision Advisers reported no remaining Qualys position as of Q2 2025 after selling out during the quarter.
PharVision Advisers sold 1,811 Qualys shares in Q2 2025, an estimated $228K.
PharVision Advisers first reported a position in Qualys in Q1 2025 and held it in 1 quarter.
PharVision Advisers's Qualys position peaked at $228K in Q1 2025.
436 funds tracked by Wall St. Rank held Qualys as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.